Literature DB >> 12547724

DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free.

Ru Chen1, Peter S Rabinovitch, David A Crispin, Mary J Emond, Kent M Koprowicz, Mary P Bronner, Teresa A Brentnall.   

Abstract

Patients with extensive ulcerative colitis (UC) of longer than 8 years duration are at high risk for the development of colorectal cancer. The cancers in these patients appear to develop in a stepwise manner with progressive histological changes from negative for dysplasia --> indefinite for dysplasia --> dysplasia --> cancer. The aim of this study was to determine the timing and extent of genomic instability in the progression of UC dysplasia and cancer. Using two polymerase chain reaction (PCR)-based DNA fingerprinting methods, arbitrarily primed PCR and intersimple sequence repeat PCR, we assessed DNA sequence variation in biopsies across the spectrum of cancerous, dysplastic, and nondysplastic mucosa. UC patients with dysplasia/cancer had substantial genomic instability in both their dysplastic and nondysplastic colonic mucosa, whereas instability was not present in the majority of UC patients without dysplasia/cancer. The degree of instability in nondysplastic tissue was similar to that of dysplastic/cancerous mucosa from the same patient, suggesting that this instability was widespread and reached the maximum level early in neoplastic progression. These results suggest that UC patients who develop dysplasia or cancer have an underlying process of genomic instability in their colonic mucosa whereas UC patients who are dysplasia-free do not.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547724      PMCID: PMC1851159          DOI: 10.1016/S0002-9440(10)63860-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  DNA polymorphisms amplified by arbitrary primers are useful as genetic markers.

Authors:  J G Williams; A R Kubelik; K J Livak; J A Rafalski; S V Tingey
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

Review 2.  Prooxidant states and tumor promotion.

Authors:  P A Cerutti
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

Review 3.  Oxidants, antioxidants, and the degenerative diseases of aging.

Authors:  B N Ames; M K Shigenaga; T M Hagen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

4.  Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.

Authors:  T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

5.  Genome fingerprinting by simple sequence repeat (SSR)-anchored polymerase chain reaction amplification.

Authors:  E Zietkiewicz; A Rafalski; D Labuda
Journal:  Genomics       Date:  1994-03-15       Impact factor: 5.736

6.  Fingerprinting genomes using PCR with arbitrary primers.

Authors:  J Welsh; M McClelland
Journal:  Nucleic Acids Res       Date:  1990-12-25       Impact factor: 16.971

7.  Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele.

Authors:  G C Burmer; P S Rabinovitch; R C Haggitt; D A Crispin; T A Brentnall; V R Kolli; A C Stevens; C E Rubin
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

8.  Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction.

Authors:  M A Peinado; S Malkhosyan; A Velazquez; M Perucho
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

Authors:  R H Riddell; H Goldman; D F Ransohoff; H D Appelman; C M Fenoglio; R C Haggitt; C Ahren; P Correa; S R Hamilton; B C Morson
Journal:  Hum Pathol       Date:  1983-11       Impact factor: 3.466

Review 10.  Reactive oxygen species in tumorigenesis.

Authors:  D I Feig; T M Reid; L A Loeb
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

View more
  29 in total

1.  The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve.

Authors:  Neil J Perkins; Enrique F Schisterman
Journal:  Am J Epidemiol       Date:  2006-01-12       Impact factor: 4.897

Review 2.  Inflammatory bowel disease: the problems of dysplasia and surveillance.

Authors:  P J Mitchell; E Salmo; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2007-11-30       Impact factor: 3.781

Review 3.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

Review 4.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

5.  Pan-colonic field defects are detected by CGH in the colons of UC patients with dysplasia/cancer.

Authors:  Lisa A Lai; Rosa Ana Risques; Mary P Bronner; Peter S Rabinovitch; David Crispin; Ru Chen; Teresa A Brentnall
Journal:  Cancer Lett       Date:  2012-03-02       Impact factor: 8.679

6.  Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.

Authors:  Joel Pekow; Urszula Dougherty; Yong Huang; Edward Gometz; Jeff Nathanson; Greg Cohen; Shawn Levy; Masha Kocherginsky; Nanda Venu; Maria Westerhoff; John Hart; Amy E Noffsinger; Stephen B Hanauer; Roger D Hurst; Alessandro Fichera; Loren J Joseph; Qiang Liu; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

7.  Up-regulation of mitochondrial chaperone TRAP1 in ulcerative colitis associated colorectal cancer.

Authors:  Ru Chen; Sheng Pan; Keith Lai; Lisa A Lai; David A Crispin; Mary P Bronner; Teresa A Brentnall
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Genomic biomarkers to improve ulcerative colitis neoplasia surveillance.

Authors:  Mary P Bronner; Jacintha N O'Sullivan; Peter S Rabinovitch; David A Crispin; Lu Chen; Mary J Emond; Cyrus E Rubin; Teresa A Brentnall
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

9.  Array-based comparative genomic hybridization in ulcerative colitis neoplasia: single non-dysplastic biopsies distinguish progressors from non-progressors.

Authors:  Mary P Bronner; Marek Skacel; David A Crispin; Peter D Hoff; Mary J Emond; Lisa A Lai; Raymond R Tubbs; Jacintha N O'Sullivan; Peter S Rabinovitch; Teresa A Brentnall
Journal:  Mod Pathol       Date:  2010-08-27       Impact factor: 7.842

Review 10.  Colon cancer stem cells: implications for prevention and therapy.

Authors:  Emina H Huang; Max S Wicha
Journal:  Trends Mol Med       Date:  2008-10-17       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.